Terms ending in 2026
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,709,511 | Novel Benzothiazolone Derivatives In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 9,562,017 | Novel Hydrogen Sulfate Salt In force · High confidence | Alexion Pharma International Operations Limited | In force | High confidence | |
| US 7,425,556 | Compounds and Uses Thereof In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 7,465,795 | Compounds and Uses Thereof In force · Medium confidence | AstraZeneca AB | In force | Medium confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.